Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis.
Binyong LiangHaichuan WangYu QiaoXue WangManning QianXinhua SongYi ZhouYi ZhangRunze ShangLi CheYifa ChenZhiyong HuangHong WuSatdarshan Paul MongaYong ZengDiego F CalvisiXiaoping ChenXin ChenPublished in: Hepatology (Baltimore, Md.) (2022)
Our studies demonstrate that YAP/TAZ are major signaling molecules downstream of LOF AXIN1 mutant HCCs, and targeting YAP/TAZ is an effective treatment against AXIN1 mutant human HCCs.